Bioatla Stock Performance

BCAB Stock  USD 0.32  0.02  5.88%   
The firm shows a Beta (market volatility) of -2.93, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bioatla are expected to decrease by larger amounts. On the other hand, during market turmoil, Bioatla is expected to outperform it. At this point, Bioatla has a negative expected return of -0.62%. Please make sure to confirm Bioatla's total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if Bioatla performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Bioatla has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
11/05/2025
2
BioAtlas Mecbotamab Vedotin , an AXL-targeting ADC, Demonstrates a Median Overall Survival of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
11/07/2025
3
Disposition of 12530 shares by Sievers Eric of Bioatla at 0.46 subject to Rule 16b-3
11/11/2025
4
BioAtla outlines 800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
11/13/2025
5
BioAtla Inc Q3 2025 Earnings Call Highlights Strategic Partnerships and Promising Trial ...
11/14/2025
6
What catalysts could drive BioAtla Inc. stock higher - 2025 Performance Recap Free Technical Confirmation Trade Alerts - newser.com
11/17/2025
7
BioAtla Enters into Agreements for up to 22.5 Million Flexible Financing
11/21/2025
8
Disposition of 1566 shares by Christian Vasquez of Bioatla at 0.904 subject to Rule 16b-3
11/28/2025
9
BioAtla and GATC Health Announce a 40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L Oropharyngea...
12/31/2025
10
Why GH Research Shares Are Trading Higher By 18 Here Are 20 Stocks Moving Premarket - Benzinga
01/05/2026
11
BioAtla stock initiated with Buy rating at Rodman Renshaw - Investing.com
01/13/2026

Bioatla Relative Risk vs. Return Landscape

If you would invest  61.00  in Bioatla on October 18, 2025 and sell it today you would lose (29.00) from holding Bioatla or give up 47.54% of portfolio value over 90 days. Bioatla is currently does not generate positive expected returns and assumes 9.3428% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than Bioatla, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Bioatla is expected to under-perform the market. In addition to that, the company is 13.36 times more volatile than its market benchmark. It trades about -0.07 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of volatility.

Bioatla Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioatla's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bioatla, and traders can use it to determine the average amount a Bioatla's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0665

High ReturnsBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsBCAB
Based on monthly moving average Bioatla is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioatla by adding Bioatla to a well-diversified portfolio.

Bioatla Fundamentals Growth

Bioatla Stock prices reflect investors' perceptions of the future prospects and financial health of Bioatla, and Bioatla fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioatla Stock performance.

About Bioatla Performance

By analyzing Bioatla's fundamental ratios, stakeholders can gain valuable insights into Bioatla's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bioatla has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bioatla has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.20)(1.26)
Return On Capital Employed(2.24)(2.13)
Return On Assets(1.20)(1.26)
Return On Equity(5.63)(5.34)

Things to note about Bioatla performance evaluation

Checking the ongoing alerts about Bioatla for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bioatla help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bioatla generated a negative expected return over the last 90 days
Bioatla has high historical volatility and very poor performance
Bioatla has some characteristics of a very speculative penny stock
Bioatla has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 11 M. Net Loss for the year was (69.78 M) with loss before overhead, payroll, taxes, and interest of (46.73 M).
Bioatla currently holds about 178.12 M in cash with (71.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from finance.yahoo.com: Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
Evaluating Bioatla's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Bioatla's stock performance include:
  • Analyzing Bioatla's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioatla's stock is overvalued or undervalued compared to its peers.
  • Examining Bioatla's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Bioatla's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioatla's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Bioatla's stock. These opinions can provide insight into Bioatla's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Bioatla's stock performance is not an exact science, and many factors can impact Bioatla's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Bioatla Stock analysis

When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm